NASDAQ: INDVIndivior Pharmaceuticals Inc Stock
$38.26+0.87 (+2.33%)
Updated Jun 9, 2026
INDV Price
$38.26
Fair Value Price
-$1.19
Market Cap
$4.66B
52 Week Low
$13.45
52 Week High
$41.00
P/E
19.03x
P/B
-32.39x
P/S
2.93x
PEG
0.7x
Dividend Yield
N/A
Revenue
$1.29B
Earnings
$251.00M
Gross Margin
81.3%
Operating Margin
25.95%
Profit Margin
19.4%
Debt to Equity
-9.31
Operating Cash Flow
-$111M
Beta
0.85
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
INDV Overview
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INDV's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
C
INDV
Ranked#1 of 52
Ranked#1 of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.20 | A | |
| $34.40 | A | |
| $14.69 | A |
Be the first to know about important INDV news, forecast changes, insider trades & much more!
INDV News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INDV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INDV ($38.26) is overvalued by 3,315.82% relative to our estimate of its Fair Value price of -$1.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INDV ($38.26) is not significantly undervalued (3,315.82%) relative to our estimate of its Fair Value price of -$1.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INDV ($38.26) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INDV due diligence checks available for Premium users.
Valuation
INDV fair value
Fair Value of INDV stock based on Discounted Cash Flow (DCF)
Price
$38.26
Fair Value
-$1.19
Undervalued by
3,315.82%
INDV ($38.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INDV ($38.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INDV ($38.26) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INDV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
19.03x
Industry
-4.55x
Market
14.33x
INDV is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INDV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
INDV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-32.39x
Industry
1.58x
INDV price to earnings growth (PEG)
For valuing profitable companies with growth potential
INDV is good value based... subscribe to Premium to read more.
PEG Value Valuation
INDV's financial health
Profit margin
Revenue
$317.0M
Net Income
$89.0M
Profit Margin
28.1%
INDV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INDV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$1.3B
Debt to equity
-9.31
INDV's short-term liabilities ($779.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INDV's short-term assets ($667.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INDV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INDV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.0M
Investing
-$19.0M
Financing
$7.0M
INDV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INDV vs Pharmaceutical Stocks
Indivior Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.